US FDA Will Leverage Current Clinical Trial Data In Deciding On Post-COVID Flexibilities

 
• By Sue Sutter
  
Yellow flag waving on the beach in the breeze against a blurred blue sky.
US FDA wants clinical datasets flagged for that period of time when a decentralized model was in place. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D